Chime Biologics And Daewoong Pharmaceutical Partner To Advance Global Dupilumab Biosimilar Development

08 June 2026 | Monday | News

Strategic collaboration combines Chime Biologics' AI enabled development platform and manufacturing capabilities with Daewoong Pharmaceutical's global expansion ambitions to accelerate access to a Dupixent biosimilar for worldwide markets.

VMS Group is pleased to share that our portfolio company, Chime Biologics, in which we are also the controlling shareholder, has announced a strategic partnership with Daewoong Pharmaceutical, a leading South Korean pharmaceutical company, for the development and manufacturing of a dupilumab biosimilar candidate referencing Dupixent® for global markets.

Chime Biologics will leverage its extensive end-to-end biosimilar development and commercialization experience, advanced AI-enabled development platform(Chime AI Platform) and bioprocess supply chain ecosystem(Chime Innovation Alliance) to support Daewoong Pharmaceutical's global biosimilar ambitions. The partnership reflects both companies' commitment to delivering high-quality and accessible biologic medicines to patients worldwide.

The programme marks Daewoong Pharmaceutical's entry into the biosimilars sector and targets the growing global immunology market. Dupixent, co-developed by Sanofi and Regeneron Pharmaceuticals, generated approximately US$17.8 billion in global sales in 2025, making it one of the world's best-selling biologic medicines.

Benny Chong, Chairman of VMS Group, said:

"At VMS Group, we back businesses that combine strong scientific capabilities with global commercial potential. Chime Biologics has built a differentiated platform serving both innovative biologics and biosimilars, and this partnership with Daewoong Pharmaceutical underscores its growing reputation as a trusted partner for world-class biopharmaceutical companies. We look forward to supporting Chime Biologics to expand its international footprint and contribute to improving patient access in advanced therapies worldwide."

Jimmy Wei, Board Director and Chief Executive Officer of Chime Biologics, commented:

"We are honored to become Daewoong Pharmaceutical's strategic partner for its entry into the global biosimilar market. Biosimilars have evolved into a highly competitive arena requiring not only scientific excellence and manufacturing robustness, but also speed, cost efficiency, and global regulatory expertise."

Chime Biologics And Daewoong Pharmaceutical Partner To Advance Global Dupilumab Biosimilar Development

Stay Connected